Longitudinal neuroimaging and neurocognitive assessment of risk and protective factors across the schizophrenia spectrum

精神分裂症谱系风险和保护因素的纵向神经影像和神经认知评估

基本信息

项目摘要

PROJECT SUMMARY Schizotypal personality disorder (SPD) is similar to schizophrenia (SZ), but with fewer and attenuated abnormalities, thus representing an important yet understudied intermediate SZ-spectrum phenotype. Examination of abnormalities in SPD will provide information regarding etiology, genetics, treatment and risk factors associated with psychosis. Although individuals with SPD demonstrate marked temporal lobe abnormalities that resemble SZ, we hypothesize that relative “sparing” or “functional enhancement” in the frontal lobes (e.g., dorsolateral prefrontal cortex), may protect these individuals from frank psychosis and the severe social and cognitive deficits typically observed in SZ. Studying SPD is powerful as antipsychotic medication and hospitalization confounds observed in SZ are not present. Moreover, there is no study examining neurobiological changes in the SZ-spectrum that incorporates individuals with SPD using a longitudinal design as proposed here. This novel approach will help disentangle potential risk and protective factors for psychosis in the SZ spectrum. This is the first longitudinal study to utilize multimodal MR imaging and Research Domain Criteria (RDoC) approaches in SZ-spectrum disorders to identify aberrant neural circuitry along a continuum from healthy controls (HCs) to SPD to SZ and examine changes in these measures in relationship to impairments in symptom severity, neurocognition and functional outcome. We propose studying three groups (80 in each) of demographically matched and rigorously diagnosed individuals (age 18- 40): HCs (no Axis I or personality disorder), unmedicated individuals with SPD (and no Axis I disorder), and early-onset (first 2 years of illness) SZ patients at baseline, 9-, and 18-month follow-up. Measures assessing frontal and temporal lobe integrity include multimodal MR imaging (structural MRI, DTI, resting-state fMRI, and task-based fMRI with a nonverbal event related working-memory task; baseline and 18-months) and neuropsychological assessment (all three timepoints). We will utilize dynamic causal modeling to test competing neurobiological models involving abnormal frontotemporal connectivity in the SZ-spectrum and machine learning approaches to integrate multimodal neuroimaging, neurocognitive, and clinical assessment data. We focus on three specific aims: (1) Investigate the longitudinal course of frontal-temporal lobe/circuitry abnormalities in the SZ-spectrum using multimodal MR imaging; (2) Investigate the longitudinal course of neurocognition, clinical, and functional outcome in the SZ spectrum; (3) Determine which factor or combination of factors differentiate groups in the SZ-spectrum to identify those that are associated with risk for and protection from SZ using machine learning.
项目总结 分裂型人格障碍(SPD)与精神分裂症(SZ)相似,但数量较少,程度较轻 异常,因此代表了一个重要但未被充分研究的中间SZ谱表型。 对SPD异常的检查将提供有关病因、遗传学、治疗和风险的信息。 与精神病有关的因素。尽管SPD患者表现出明显的颞叶 类似于SZ的异常,我们假设 额叶(例如,背外侧前额叶皮质)可以保护这些人免受坦率的精神病和 严重的社会和认知缺陷通常在深圳观察到。研究SPD是一种强大的抗精神病药物 在深圳观察到的用药和住院混淆并不存在。此外,也没有研究 检查SZ谱中的神经生物学变化,该谱结合了SPD患者 这里提出的纵向设计。这一新的方法将有助于理清潜在的风险和保护 SZ谱系中的精神病因素。这是第一次利用多模式磁共振成像进行纵向研究。 和研究领域标准(RDoC)方法在SZ谱系障碍中识别异常神经 从健康对照组(HCS)到SPD再到SZ的连续回路,并检查这些指标的变化 与症状严重程度、神经认知和功能结果的损害有关。我们建议 研究了三组(每组80人)的人口统计匹配和严格诊断的个人(18岁- 40):HCS(无轴心I或人格障碍),未服药的SPD患者(无轴心I障碍),以及 基线、9个月和18个月随访的早发性(患病头2年)SZ患者。措施评估 额叶和颞叶的完整性包括多模式磁共振成像(结构MRI、DTI、静息状态fMRI和 基于任务的功能磁共振成像,采用非语言事件相关工作记忆任务;基线和18个月)和 神经心理评估(所有三个时间点)。我们将利用动态因果模型来测试 相互竞争的神经生物学模型涉及SZ频谱中异常的额颞部连接和 集成多模式神经成像、神经认知和临床评估的机器学习方法 数据。本研究的主要目的有三:(1)研究额-颞叶/环路的纵向运动过程 应用多模式磁共振成像研究SZ谱的异常;(2)研究SZ谱的纵向过程 SZ谱中的神经认知、临床和功能结果;(3)决定哪种因素或组合 的因素来区分SZ谱中的群体,以识别那些与罹患和 使用机器学习保护SZ。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

ERIN A. HAZLETT其他文献

ERIN A. HAZLETT的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('ERIN A. HAZLETT', 18)}}的其他基金

CSRD Research Career Scientist Award Application
CSRD研究职业科学家奖申请
  • 批准号:
    10701136
  • 财政年份:
    2023
  • 资助金额:
    $ 100.32万
  • 项目类别:
A Novel Cognitive Remediation Intervention Targeting Poor Decision-Making and Depression in Veterans at High Risk for Suicide: A Safe,Telehealth Approach During the COVID-19 Pandemic
针对自杀高风险退伍军人的决策失误和抑郁症的新型认知补救干预措施:COVID-19 大流行期间的安全远程医疗方法
  • 批准号:
    10366431
  • 财政年份:
    2022
  • 资助金额:
    $ 100.32万
  • 项目类别:
A Novel Cognitive Remediation Intervention Targeting Poor Decision-Making and Depression in Veterans at High Risk for Suicide: A Safe,Telehealth Approach During the COVID-19 Pandemic
针对自杀高风险退伍军人的决策失误和抑郁症的新型认知补救干预措施:COVID-19 大流行期间的安全远程医疗方法
  • 批准号:
    10539275
  • 财政年份:
    2022
  • 资助金额:
    $ 100.32万
  • 项目类别:
Longitudinal neuroimaging and neurocognitive assessment of risk and protective factors across the schizophrenia spectrum
精神分裂症谱系风险和保护因素的纵向神经影像和神经认知评估
  • 批准号:
    10381940
  • 财政年份:
    2020
  • 资助金额:
    $ 100.32万
  • 项目类别:
Longitudinal neuroimaging and neurocognitive assessment of risk and protective factors across the schizophrenia spectrum
精神分裂症谱系风险和保护因素的纵向神经影像和神经认知评估
  • 批准号:
    10319171
  • 财政年份:
    2020
  • 资助金额:
    $ 100.32万
  • 项目类别:
CSR&D Research Career Scientist Award Application
企业社会责任
  • 批准号:
    10177966
  • 财政年份:
    2018
  • 资助金额:
    $ 100.32万
  • 项目类别:
CSR&D Research Career Scientist Award Application
企业社会责任
  • 批准号:
    10426091
  • 财政年份:
    2018
  • 资助金额:
    $ 100.32万
  • 项目类别:
CSR&D Research Career Scientist Award Application
企业社会责任
  • 批准号:
    9892965
  • 财政年份:
    2018
  • 资助金额:
    $ 100.32万
  • 项目类别:
CSR&D Research Career Scientist Award Application
企业社会责任
  • 批准号:
    9551820
  • 财政年份:
    2018
  • 资助金额:
    $ 100.32万
  • 项目类别:
Neurobiology of Affective Instability in Veterans at Low and High Risk for Suicide
低自杀风险和高自杀风险退伍军人情感不稳定的神经生物学
  • 批准号:
    10311973
  • 财政年份:
    2017
  • 资助金额:
    $ 100.32万
  • 项目类别:

相似海外基金

Drug Interactions Involving Second-generation Antipsychotic Agents Leading to Sudden Cardiac Arrest
涉及第二代抗精神病药物的药物相互作用导致心脏骤停
  • 批准号:
    10661090
  • 财政年份:
    2022
  • 资助金额:
    $ 100.32万
  • 项目类别:
Drug Interactions Involving Second-generation Antipsychotic Agents Leading to Sudden Cardiac Arrest
涉及第二代抗精神病药物的药物相互作用导致心脏骤停
  • 批准号:
    10501196
  • 财政年份:
    2022
  • 资助金额:
    $ 100.32万
  • 项目类别:
Possible mechanism of action of metabolic syndrome induction in patients treated with atypical antipsychotic agents
使用非典型抗精神病药物治疗的患者诱导代谢综合征的可能作用机制
  • 批准号:
    22590157
  • 财政年份:
    2010
  • 资助金额:
    $ 100.32万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
The use of atypical antipsychotic agents and the risk of breast cancer
非典型抗精神病药物的使用和乳腺癌的风险
  • 批准号:
    192724
  • 财政年份:
    2009
  • 资助金额:
    $ 100.32万
  • 项目类别:
    Operating Grants
Indolobenzox- and Thiazepines as Atypical Antipsychotic Agents
吲哚苯氧和硫氮卓类药物作为非典型抗精神病药
  • 批准号:
    7539253
  • 财政年份:
    2008
  • 资助金额:
    $ 100.32万
  • 项目类别:
Ectopic activators of M1 as novel antipsychotic agents
M1 异位激活剂作为新型抗精神病药物
  • 批准号:
    7676049
  • 财政年份:
    2007
  • 资助金额:
    $ 100.32万
  • 项目类别:
Ectopic activators of M1 as novel antipsychotic agents
M1 异位激活剂作为新型抗精神病药物
  • 批准号:
    7626881
  • 财政年份:
    2007
  • 资助金额:
    $ 100.32万
  • 项目类别:
Ectopic activators of M1 as novel antipsychotic agents
M1 异位激活剂作为新型抗精神病药物
  • 批准号:
    7333930
  • 财政年份:
    2007
  • 资助金额:
    $ 100.32万
  • 项目类别:
Muscarinic receptor activators as antipsychotic agents
作为抗精神病药物的毒蕈碱受体激活剂
  • 批准号:
    7034693
  • 财政年份:
    2006
  • 资助金额:
    $ 100.32万
  • 项目类别:
Muscarinic receptor activators as novel antipsychotic agents
毒蕈碱受体激活剂作为新型抗精神病药
  • 批准号:
    7163800
  • 财政年份:
    2006
  • 资助金额:
    $ 100.32万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了